Edesa Biotech Inc expected to post a loss of 17 cents a share - Earnings Preview

Edesa Biotech

09/05/2023 19:32

* Edesa Biotech Inc  EDSA.OQ   EDSA.O  is expected to show
no
change in quarterly revenue when it reports  results on May 11
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Edesa Biotech Inc
is for
a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Edesa
Biotech Inc
is $13​, above​ its last closing price of $1.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.19       -0.19      -0.13     Beat    31.6
 Sep. 30 2022              -0.39      -0.02     Beat    94.9
 Jun. 30 2022  -0.43       -0.43      -0.37     Beat    14​
 Mar. 31 2022  -0.34       -0.37      -0.33     Beat    10
 ​​Dec.        -0.40       -0.40      -0.33     Beat    17.5
 31 2021                                                
 Sep. 30 2021  -0.41       -0.37      -0.27     Beat    26.4​
 Jun. 30 2021  -0.32       -0.32      -0.36     Missed  -12.5
 Mar. 31 2021  -0.29       -0.29      -0.81     Missed  -174.6
 This summary was machine generated May 9 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated